Publication date: Jun 25, 2025
Candida (Candidozyma) auris, a multidrug resistant organism, can cause severe, invasive infections. We characterized C. auris epidemiology in New York before and during the COVID-19 pandemic. Multiple statewide databases were linked to assess demographic and clinical characteristics and outcomes among C. auris screening cases (patients tested for colonization screening) and clinical cases (patients tested to diagnose disease). Cases diagnosed during 2017-2022 were divided into four phases and compared, including pre-COVID-19, first wave, ongoing mitigation, and vaccine era. Joinpoint analysis was used to assess monthly percentage change (MPC) and significant temporal trends among clinical cases. During the first wave, higher proportions of C. auris cases were among Black and Hispanic patients (clinical and screening), patients from high social vulnerability index neighborhoods (clinical), and patients aged
| Concepts | Keywords |
|---|---|
| Databases | Candida auris |
| Hispanic | COVID-19 |
| Pandemic | emerging diseases |
| Vaccine | infection control |
| multidrug resistance |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 pandemic |
| disease | IDO | organism |
| disease | MESH | infections |
| disease | MESH | social vulnerability |
| disease | IDO | infection |